Xenetic Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Xenetic Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.98M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.50M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.54M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.71M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.16M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $436.9K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $17.1K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $7.59M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $3.00M | Mar 30, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Apr 15, 2015 |
| FY2013 | Dec 31, 2013 | $1.00M | Jul 20, 2015 |
| FY2013 | Dec 31, 2012 | $248.8K | Jul 20, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.68M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($3.96M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($4.13M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($6.55M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($5.65M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($10.89M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($12.78M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($7.30M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($3.60M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($54.21M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.83M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($4.20M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($4.52M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($6.72M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($5.75M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($13.94M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($12.89M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($7.28M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($3.57M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($47.43M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.07M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.29M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.49M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $4.77M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.16M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.73M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $4.89M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $2.88M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $4.06M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $43.74M | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.29M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($2.82M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($4.11M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($4.65M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($4.74M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($4.27M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($6.40M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($6.46M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.49M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($8.79M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $9.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $16.8K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $1.7K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $57.7K | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | $78.6K | Jul 20, 2015 |
| FY2013 | Aug 31, 2013 | $212.5K | Nov 27, 2013 |
| FY2013 | Dec 31, 2012 | $130.1K | Jul 20, 2015 |
| FY2012 | Aug 31, 2011 | $212.5K | Dec 14, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.36M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.90M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $10.61M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $14.72M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $19.82M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $13.18M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $21.55M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $14.43M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $19.16M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $20.97M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $968.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $894.3K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $809.6K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.07M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.42M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $964.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $4.33M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $4.52M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $4.86M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.80M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.40M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.01M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $9.80M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $13.65M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $18.39M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $12.22M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $17.21M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $9.91M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $14.30M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $16.17M | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $0 | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | $9.24M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $3.28M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $3.28M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.28M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $3.28M | Mar 30, 2018 |
| FY2016 | Dec 31, 2014 | $3.47M | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $3.67M | Mar 30, 2016 |
| FY2013 | Dec 31, 2012 | $3.59M | Jul 20, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($199.88M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($197.19M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($193.23M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($189.10M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($182.55M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($176.90M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($166.01M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($153.23M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($145.93M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($142.34M) | Mar 30, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.29M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 1.54M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 1.54M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 1.52M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 13.44M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 8.75M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 6.07M | Mar 16, 2021 |
| FY2018 | Dec 31, 2018 | 9.40M | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | 8.72M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 4.59M | Mar 30, 2018 |